A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis

Cureus. 2022 Jun 10;14(6):e25818. doi: 10.7759/cureus.25818. eCollection 2022 Jun.


Empagliflozin-induced euglycemic diabetic ketoacidosis is a life-threatening metabolic complication of diabetes mellitus characterized by metabolic acidosis, ketonemia, and relatively normal serum glucose levels. We present a rare case of empagliflozin-induced diabetic ketoacidosis obscured by alkalosis. This case report aims to create awareness among clinicians about this entity and consider this diagnosis in their differential, especially in patients taking sodium-glucose co-transporter (SGLT-2) inhibitors who present to the hospital with unspecific symptoms that may not suggest DKA.

Keywords: alkalosis; diabetic keto-alkalosis; diabetic ketoacidosis (dka); euglycemic diabetic ketoacidosis; sodium glucose co-transporter 2 inhibitors (sglt2i).

Publication types

  • Case Reports